The estimated Net Worth of Joshua A Kazam is at least $1.78 Million dollars as of 12 January 2022. Mr. Kazam owns over 15,000 units of Allogene Therapeutics Inc stock worth over $753,355 and over the last 11 years he sold ALLO stock worth over $0. In addition, he makes $1,028,880 as Co-Founder und Director at Allogene Therapeutics Inc.
Joshua has made over 6 trades of the Allogene Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 15,000 units of ALLO stock worth $189,000 on 12 January 2022.
The largest trade he's ever made was buying 15,000 units of Allogene Therapeutics Inc stock on 12 January 2022 worth over $189,000. On average, Joshua trades about 1,002 units every 61 days since 2013. As of 12 January 2022 he still owns at least 258,885 units of Allogene Therapeutics Inc stock.
You can see the complete history of Mr. Kazam stock trades at the bottom of the page.
Joshua A. Kazam serves as Co-Founder, Director of the Company. Mr. Kazam served as our President from November 2017 until June 2018. He was a founder of Kite and served as a member of Kite’s board of directors from Kite’s inception in June 2009 until October 2017. In June 2009, Mr. Kazam co-founded Two River Consulting, LLC, a life-science consulting and investment firm. Mr. Kazam has served on the board of Vision Path, Inc. (d/b/a Hubble Contacts) since May 2016, ByHeart, Inc. since November 2016, Kronos Bio, Inc. since June 2017, Breakthrough Properties LLC and Breakthrough Services LLC since April 2019, and Flying Eagle Acquisition Corp. since February 2020. Mr. Kazam previously served as a director of Diamond Eagle Acquisition Corp. from January 2019 until April 2020, Capricor Therapeutics, Inc. from May 2005 until May 2019 and Platinum Eagle Acquisition Corp. from January 2018 to March 2019. Platinum Eagle Acquisition Corp., Diamond Eagle Acquisition Corp. and Flying Eagle Acquisition Corp. are blank check companies formed for the purpose of effecting a business combination with one or more businesses. Mr. Kazam has served as the President of Desert Flower Foundation since June 2016. Mr. Kazam received his bachelor’s degree in Entrepreneurial Management from the Wharton School of the University of Pennsylvania and is a Member of the Wharton School’s Undergraduate Executive Board.
As the Co-Founder und Director of Allogene Therapeutics Inc, the total compensation of Joshua Kazam at Allogene Therapeutics Inc is $1,028,880. There are 6 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Joshua Kazam is 43, he's been the Co-Founder und Director of Allogene Therapeutics Inc since 2018. There are 18 older and 2 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Joshua's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 400, SAN MATEO, CA, 94402.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun und Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: